Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer

Journal of Surgical Oncology

Volumn 111, Issue 2, 2015, Pages 198-202

  Connor, Carol S ^a   Kimler, Bruce F ^b   Mammen, Joshua M V ^a   Mcginness, Marilee K ^a   Wagner, Jamie L ^a   Alsop, Samantha M ^a   Ward, Claire ^a   Fabian, Carol J ^a   Khan, Qamar J ^a   Sharma, Priyanka ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Axillary lymph node dissection; Clinically axillary lymph node negative; Neoadjuvant chemotherapy; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER SURGERY; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; AXILLA; CLINICAL TRIAL; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; REGISTER; SEGMENTAL MASTECTOMY; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; REGISTRIES; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84921598530     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23790     Document Type: Article

References (25)

1. Goldhirsch A, Winer EP, Coates AS, et al.: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-2223.
2. Dent R, Trudeau M, Pritchard KI, et al.: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434.
3. Haffty BG, Yang Q, Reiss M, et al.: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
4. Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
5. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer. National Comprehensive Cancer Network; 2014. Available at: www.nccn.org.
6. Carey LA, Dees EC, Sawyer L, et al.: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
7. Cortazar P, Zhang L, Untch M, et al.: Pathological complete response and long -term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014;384:164-172.
8. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
9. von Minckwitz G, Untch M, Blohmer JU, et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804.
10. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
11. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
12. Mamounas EP, Brown A, Anderson S, et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-2702.
13. Xing Y, Foy M, Cox DD, et al.: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:539-546.
14. Surgeons ASoB: Position statement on management of the axilla in patients with invasive breast cancer; 2011. Available at: www.breastsurgeons.org.
15. Guarneri V, Broglio K, Kau SW, et al.: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
16. Huober J, von Minckwitz G, Denkert C, et al.: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-140.
17. Jones T, Neboori H, Wu H, et al.: Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? Ann Surg Oncol 2013;20:2866-2872.
18. Hammond MEH, Hayes DF, Dowsett M, et al.: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010;28:2784-2795.
19. Harris PA, Taylor R, Thielke R, et al.: Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
20. Mansel RE, Fallowfield L, Kissin M, et al.: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
21. von Minckwitz G, Untch M, Nuesch E, et al.: Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011;125:145-156.
22. Sharma P, Khan Q, Kimler B, et al.: Results of a phase II study of neoadjuvant platinum/taxane based chemotherapy and erlotinib for Triple Negative Breast Cancer [abstract]. Cancer Res 2010;70:P1-11-07.
23. Mahmood U, Hanlon AL, Koshy M, et al.: Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 2013;20:1436-1443.
24. Pesce CE, Liederbach E, Czechura T, et al.: Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: A report from the National Cancer Data Base. J Am Coll Surg 2014;219:19-28.
25. Yen TW, Laud PW, Sparapani RA, et al.: Surgeon specialization and use of sentinel lymph node biopsy for breast cancer. JAMA Surg 2014;149:185-192.